NASDAQ, STTK #Discontinuation #Financial Data #Letter to Shareholders #Syndromes Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates February 23, 2023 16:30 EST – Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer – – Dosed patients in first combination cohort with azacitidine in ongoing Phase 1A/B clinical trial of SL-172154 in acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) – – Announced two No Comments
NASDAQ, NURO #Negative Financials #Syndromes #Trending News NeuroMetrix Reports Q4 and Full Year 2022 Financial Results February 23, 2023 07:00 EST WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company’s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through No Comments
FIXX, NASDAQ #Event #New Clinical Trial Data #Syndromes #Trending News Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting February 22, 2023 16:01 EST Preclinical Studies Demonstrated a Targeted Immunosuppression Approach Led to Reduced Immune Response to AAVHSC Administration and Improved Gene Expression In Vivo Gene Therapy Candidate HMI-204 for MLD Showed Robust CNS Distribution and Expression with Improved Packaging Productivity BEDFORD, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: No Comments
NASDAQ, RGNX #Positive Clinical Trial Results #Syndromes #Trending News Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO’s RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM February 22, 2023 15:00 EST RGX-121, a potential one-time gene therapy for the treatment of MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels Additional data from patients in Cohort 3 using pivotal program dose level continue to demonstrate largest reductions in CSF GAGs, continuing to approach normal levels No Comments
NASDAQ, SNSE #New Clinical Trial Data #Syndromes #Trending News Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics February 21, 2023 07:30 EST BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, presented preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, in an oral presentation at Next Generation Antibody Therapeutics: From Discovery No Comments
NASDAQ, PHAR #New Clinical Trial Data #Syndromes #Trending News Pharming announces first patient enrolled in pediatric clinical trial of leniolisib February 21, 2023 01:00 EST The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands, Feb. 21, 2023 /PRNewswire/ — Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been enrolled in its No Comments
JSPR, NASDAQ #Merger #New Employee #Syndromes Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors February 17, 2023 08:20 EST REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell No Comments
JSPR, NASDAQ #Event #New Clinical Trial Data #Syndromes #Trending News Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR February 17, 2023 08:10 EST Both Fanconi Anemia patients treated with briquilimab successfully engrafted with neutrophil engraftment within 11 days 100% total donor chimerism was achieved through six months for the first patient and through three months for the second patient Both patients are doing well post-transplant with briquilimab-based conditioning REDWOOD CITY, Calif., Feb. No Comments
NASDAQ, RGNX #New Clinical Trial Data #Syndromes #Trending News REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023 February 17, 2023 07:05 EST New interim data from Phase I/I/III trial of RGX-121 for the treatment of MPS II and Phase I/II trial of RGX-111 for the treatment of MPS I to be presented ROCKVILLE, Md., Feb. 17, 2023 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and eight poster No Comments
JSPR, NASDAQ #Featured #Positive Clinical Trial Results #Syndromes #Trending News Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients February 16, 2023 16:05 EST First two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-up Third sickle cell disease participant has now achieved 100% donor myeloid chimerism through 30 days follow-up All three participants have increased their hemoglobin at last follow-up relative to baseline REDWOOD CITY, Calif., Feb. No Comments
Tactile Systems Technology, Inc. Announces Pricing of $32.5 Million Public Offering of Common Stock 02/23/2023
Columbia Banking System Set to Join S&P MidCap 400; Verra Mobility to Join S&P SmallCap 600 02/23/2023
NIO’s F4 plant will be located in Chuzhou to produce models for Firefly sub-brand, report says 02/20/2023